急性重症胰腺炎早期容量治疗的临床观察

Clinical observation on severe acute pancreatitis at early stage of volume therapy

目的提高对重症急性胰腺炎的认识,观察容量治疗重症胰腺炎的临床疗效和安全性。方法将80例急性胰腺炎患者随机分为观察组40例和对照组40例,对照组给予常规晶体液生理盐水注射液容量支持,治疗组在常规晶体液生理盐水注射液联合羟乙基淀粉注射液容量支持。观察两组治疗前后临床指标的变化。结果治疗组的全身炎症反应综合征、肠鸣音恢复时间、血淀粉酶恢复正常时间、C-反应蛋白持续时间、平均住院时间均短于对照组(P<0.05),治疗组的总有效率显著高于对照组(P<0.05),治疗组的并发症发生率显著低于对照组(P<0.05)。结论重症急性胰腺炎急性反应期宜早期行容量支持,疗效可靠,并能减少并发症。

Objective To improve the severe acute pancreatitis understanding, and observe clinical efficacy and safety on capacity treatment for severe acute pancreatitis. Methods 80 cases of acute pancreatitis patients were randomly di- vided into observation group of 40 cases and control group of 40 cases, control group was given Regular Crystal Fluid Physiological Saline Injection capacity support, the treatment group was given the Conventional Crystal Fluid Physio- logical Saline Injection combined with Hydroxyethyl Starch Injection capacity support. Results Systemic inflammatory response syndrome, bowel sound recovery time, blood amylase restore normal time, C-reactive protein duration, the average hospitalization time of treatment group were shorter than that in control group （P 〈 0.05）, the treatment group＇s total effective rate was significantly higher than that in control group （P 〈 0.05）, the rates significantly lower than that in control group （P 〈 0.05）. Conclusion Severe acute riod should be early line capacity support, curative effect is reliable, and can reduce the treatment group＇s complication pancreatitis acute reaction pc- complications.